Ipsen S.A. publishes its 2023 Consolidated Financial Statements

Ipsen nominates Peter Guenter to its Board of Directors

Pierrick Lefranc appointed as Executive Vice President Technical Operations, member of Executive Leadership Team

Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia

Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

Ipsen mourns the passing of Henri Beaufour, a founding family Board member

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue